The ATAC Research Fund at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona, was founded in 2005 by Troy Richards, a nine year Adrenocortical Carcinoma (ACC) survivor. With the goal of having research dedicated solely to ACC, the ATAC Fund is now one of the largest ACC research projects in the world, already discovering hopeful new targets, producing more data than ever before and using tools never before used for ACC research. Special funds help the TGen Foundation raise critical funds to support research.
Adrenocortical carcinoma is a rare and aggressive cancer of the adrenal cortex that affects only one or two people in a million.
In two short years, the ATAC Fund has raised $792,358 for ACC research through special events, donations and grants. TGen's ongoing ACC research project involves utilizing the most up-to-date genomic technologies to develop more effective treatments for this rare and devastating cancer.